Lamivudine is a nucleoside analogue reverse transcriptase inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Limitations of Use: The dosage of this product is for HIV-1 and not for HBV.
Dosage and Side Effects
Adults: 300 mg daily, administered as either 150 mg twice daily or 300 mg once daily.
Pediatric Patients Aged 3 Months and Older: Administered either once or twice daily. Dose should be calculated on body weight (kg) and should not exceed 300 mg daily.
Patients with Renal Impairment: Doses of Lamivudine must be adjusted in accordance with renal function.
The most common reported adverse reactions (incidence greater than or equal to 15%) in adults were headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough.
The most common reported adverse reactions (incidence greater than or equal to 15%) in pediatric subjects were fever and cough.